GenEdit: Funding, Investors & Team (Sep 2026)
The purpose of GenEdit's establishment is to revolutionize gene therapies by developing advanced non-viral, gene editing-based treatments. GenEdit has introduced the NanoGalaxy™ platform, a unique technology that tackles existing issues in delivering gene therapies. This platform efficiently screens a library of nanoparticles to ensure safer and more effective delivery to specific tissues. By utilizing GenEdit's tool, therapeutic gene editing becomes more accessible, quicker, and more precise compared to previous gene-editing methods. Consequently, this technology has the potential to be extensively applied in curing genetic diseases that were previously considered incurable, empowering healthcare professionals to offer permanent solutions.
GenEdit has raised $24.0M across 1 funding round on record, the most recent a Series A of $24.0M announced in Jan 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
GenEdit Company Profile and Key Stats
Latest funding round on record: Jan 2024.
GenEdit Funding Rounds
GenEdit Founders and Leadership Team
No contact details are on record for this team yet.
GenEdit Funding Compared to Other Biotechnology Startups
GenEdit's latest round of $24.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like GenEdit in Biotechnology and South San Francisco
Companies Similar to GenEdit
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
GenEdit Funding FAQs
What does GenEdit do?
The purpose of GenEdit's establishment is to revolutionize gene therapies by developing advanced non-viral, gene editing-based treatments. GenEdit has introduced the NanoGalaxy™ platform, a unique technology that tackles existing issues in delivering gene therapies. This platform efficiently screens a library of nanoparticles to ensure safer and more effective delivery to specific tissues. By utilizing GenEdit's tool, therapeutic gene editing becomes more accessible, quicker, and more precise compared to previous gene-editing methods. Consequently, this technology has the potential to be extensively applied in curing genetic diseases that were previously considered incurable, empowering healthcare professionals to offer permanent solutions.
How much funding has GenEdit raised?
GenEdit has raised $24.0M across 1 round on record. The most recent is a Series A of $24.0M announced in Jan 2024.
When did GenEdit last raise funding?
GenEdit's most recent funding round on record is a Series A of $24.0M, announced in Jan 2024.
Who founded GenEdit?
FundedIQ lists Niren Murthy (Founder) at GenEdit.
Where is GenEdit headquartered?
GenEdit is based in South San Francisco, California, United States.
How many employees does GenEdit have?
GenEdit is in the 11-50 employee band.
How does GenEdit's funding compare to other Biotechnology startups?
GenEdit's latest round of $24.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's GenEdit Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for GenEdit is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.